Learn more about how we can support your work
Started by proven leaders in the health care industry with a track record of building successful healthcare and managed care companies. After their previous companies were sold to Fortune 50 healthcare companies, this team is ready for the next challenge and setting their sites on improving the management of gene and cell therapy solutions.
By streamlining the supply chain, we drive down cost for payers to increase the rate of innovation for life-saving treatments. Because of the unique case of each person and the academic nature of gene therapy, higher levels of support are needed for healthcare providers. We remove barriers in management, reimbursement and financing, offering a higher level of business continuity and efficiency in emerging gene and cell therapies.
By working with us, we help decrease cost allowing you to focus on more strategic partnerships. Cover more ground in partnership with ETS. Complex emerging therapies involves more specialized work than buying and administering drugs. It requires an intricate handoffs between providers, coding, billing and payment. We take care of everything from negotiating contracts to claims administration and everything in between.
Emerging Therapy Solutions is created by industry veterans of managed care solutions and healthcare biotech.
With 40 years of experience in the health care and managed care industries, Dave brings extensive experience as a successful leader and executive. Dave was Chairman/CEO of Medication Management Systems, Inc., a pharmaceutical care management company, that was acquired by Genoa HealthCare (2017). Previously, Dave was CEO of NovoLogix, a medical pharmacy technology company, that was acquired by CVS (2013). Past roles include: CEO of RxHub, an electronic prescribing company; CEO of United Resource Networks at United Health Group, that managed organ and tissue transplants for 45 million payer lives; SVP American MedCenters, an HMO management company where he managed provider contracting, reinsurance subsidiary services, and PBM services.
Dave holds a BS in Pharmacy from Ohio State University and a PhD from the University of Minnesota.
Previously, Marnie served as Director, Business Development and Integration in the Health and Care Engagement Division at HealthPartners. Areas of responsibility included directing new business development, relationship management, geographic expansion of care coordination strategies in Iowa, Wisconsin, North and South Dakota, high cost case strategies, and enterprise wide affordability facilitation. All work focused on the triple AIM (experience, quality and affordability) delivering a personalized, integrated and seamless experience for patients and members. She also has over ten years experience at UnitedHealth Group where she developed deep insight into high cost reinsurance strategies, program design, consumerist concepts, and development of nationally networked centers of excellence.
Marnie is a graduate of the College of St. Catherine in Nursing and has been invited to speak nationally and is published.
A 20-year veteran in health care and managed care industries, Ashley Hume brings extensive experience leading multidisciplinary teams in both the provider and managed care spaces. Most recently, Ashley was Director of Provider Relations for Blue Cross and Blue Shield of Minnesota, focused on network management and provider relations. Previously, Ashley has lead Revenue Cycle operations for multiple specialty groups gaining significant expertise in prior authorization, claims and patient financial services; as well as third-party payor contracting, direct-to-employer contracting and physician services contracting. Ashley also served as Vice President of Operations for NovoLogix, a medical pharmacy technology company acquired by CVS (2013). Past roles include Director of Business Services for Fairview Southdale hospital as well as multiple consulting engagements related to software development for healthcare services.
Matt has been a healthcare-focused venture capital investor since 1980. He began his venture capital career with Citicorp Venture Capital, where he was VP and a member of the investment executive committee. Matt later joined Robertson, Stephens & Co. and was partner and Chairman of the Venture Capital Group. In 1991 he formed Mackowski & Shepler, an investment partnership focused on developing life science and medical technology companies and the predecessor to THP. Matt has represented THP on the boards of Kinetikos Medical (acquired by Integra), Ambion (acquired by Applied Biosystems), Aurora Discovery (acquired by NEXUS Biosystems), Interface Associates (acquired by NDC), Asuragen, Althea Technologies (acquired by Ajinomoto), AltheaDx, MedPricer, Magstim and TrakCel.
Kevin has extensive knowledge and experience in health care and health care transactions. His primary goal is to help small and medium sized health care companies grow successfully and maximize their value. Kevin has a law degree and an MBA from the University of Minnesota. His experience spans law, healthcare, and mergers and acquisitions, having participated in over 70 transactions.
Dave is a veteran in the health care industry and is the founder and CEO of Emerging Therapy Solutions. A seasoned CEO and founder of several managed care software companies that were acquired by companies like CVS and Genoa HealthCare. He also has previous leadership experience as the CEO of RxHub, CEO of United Resource Networks at UHG, and SVP at American MedCenters.
Ravi is a seasoned CEO and founder with a strong background in finance and healthcare and clinical services. Ravi was the CFO of Biotec Services International and has extensive leadership experience in finance, health, biotech, safety and environmental functions. Ravi has a BSc in Biochemistry and Molecular Biology from Cardiff University.
Jeanette has worked in the areas of private equity, mergers & acquisitions, securities law and administration since 1990. Jeanette worked at Three Cities Research, a private equity firm in New York focused on middle market companies. Her private equity investment activities range from growth equity and leveraged buyouts to going private transactions and bankruptcy auctions.
Get in touch with the team.